Innohep

Tinzaparin Sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a sterile solution for subcutaneous use. It is employed to prevent and treat venous thrombo‑embolism in patients at risk, including those undergoing surgery. GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Innohep, a low molecular weight heparin, is used in clinical situations where inhibition of clot formation is required. - Deep vein thrombosis (prevention): Reduces the incidence of clot formation in at‑risk patients. - Deep vein thrombosis (treatment): Promotes resolution of existing thrombi and prevents extension. - Pulmonary embolism (prevention): Lowers the risk of embolic events after major surgery or immobilisation. - Surgical anticoagulation: Provides peri‑operative anticoagulation to minimise postoperative thrombotic complications.

Common Side Effects: - Injection site erythema or bruising: Local irritation at the subcutaneous site. - Minor bleeding: Nosebleeds, gum bleeding, or easy bruising. - Headache: Mild to moderate discomfort. - Nausea: Transient gastrointestinal upset. - Elevated liver enzymes: Mild, reversible changes in hepatic labs.

Serious or Rare Side Effects: - Major hemorrhage: Life‑threatening bleeding requiring medical intervention. - Heparin‑induced thrombocytopenia (HIT): Immune‑mediated platelet decline with paradoxical clot risk. - Spinal or epidural hematoma: Bleeding in the central nervous system after neuraxial procedures. - Severe allergic reaction: Anaphylaxis or systemic urticaria. - Acute adrenal hemorrhage: Rare but potentially fatal adrenal bleeding.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients closely. - Renal function assessment: Adjust dosing in patients with impaired clearance. - Platelet count monitoring: Detect early signs of HIT. - Bleeding risk evaluation: Review history of recent surgery or trauma. - Concomitant anticoagulant use: Avoid or adjust doses of other blood thinners. - Elderly patients: Use caution due to increased sensitivity. - Store at 2‑8°C: Keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct oral anticoagulants): Heightened bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): Additive antithrombotic effect. - Fibrinolytic therapy (e.g., alteplase): Potentiates hemorrhage. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): Increases mucosal bleeding. - Neuraxial anesthesia or spinal puncture: Risk of spinal hematoma.

Moderate Interactions (Monitor Closely): - ACE inhibitors: May enhance hypotensive effects. - Diuretics: Potential for volume depletion and renal impact. - Certain antibiotics (e.g., vancomycin): May alter platelet function. - Hormonal contraceptives: Slight increase in thrombotic tendency. - Lipid‑lowering agents (e.g., statins): Monitor liver enzymes.